Postmarketing Drug Safety Surveillance

2003 ◽  
Vol 1 (4) ◽  
pp. 231-244 ◽  
Author(s):  
Jasmanda H. Wu ◽  
Man C. Fung ◽  
Kenneth Kwong ◽  
Kenneth Hornbuckle ◽  
Edmundo Muniz
Keyword(s):  
Drug Safety ◽  
Safety Surveillance ◽  
Drug Safety Surveillance

Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China

Drug Safety ◽  
2017 ◽  
Vol 41 (1) ◽  
pp. 125-137 ◽  
Author(s):  
Yu Yang ◽  
Xiaofeng Zhou ◽  
Shuangqing Gao ◽  
Hongbo Lin ◽  
Yanming Xie ◽  
...  
Keyword(s):  
Drug Safety ◽  
Safety Surveillance ◽  
Electronic Healthcare Databases ◽  
Drug Safety Surveillance ◽  
Post Marketing

scholarly journals A drug safety surveillance study of a ciprofloxacin / dexamethasone ophthalmic fixed combination in Peruvian population

2020 ◽  
Author(s):  
Homero Contreras-Salinas ◽  
Leopoldo Martín Baiza-Durán ◽  
Mariana Barajas-Hernández ◽  
Alan Omar Vázquez-Álvarez ◽  
Lourdes Yolotzin Rodríguez-Herrera
Keyword(s):  
Drug Safety ◽  
Concomitant Medication ◽  
Fixed Combination ◽  
Real Life ◽  
Prescribing Patterns ◽  
Surveillance Study ◽  
Phone Calls ◽  
Safety Surveillance ◽  
Drug Safety Surveillance ◽  
Post Marketing

(1) Background: drugs provide a significant benefit; however, their use implies an intrinsic potential danger, with the possibility to cause unwanted effects. These effects are known as adverse drug reactions (ADRs). Post-marketing drug safety surveillance detects unknown risks that have not been identified in clinical trials and it is necessary to monitor marketed medications under real-life practice. Due to the scarce information about fixed combination of ciprofloxacin 0.3% / dexamethasone 0.1% (SDO), we performed a drug safety surveillance study. (2) Methods: A prospective non-controlled drug safety surveillance study was conducted in Peruvian population. A total of 236 patients prescribed SDO were included derivates from 12 sites. Patients' standardized information was collected through two phone calls, including demographics, medical history, prescribing patterns of SDO, concomitant medication, and ADRs in detail. The ADRs were classified by causality and severity, followed by outcome measures to identify new risk. (3) Results: 236 patients prescribed with SDO participated in the study and 220 were included. A total of 82 ADRs/220 patients were reported after the use of SDO, presenting a ratio 0.37 ADR/patient. The most frequent ADR with SDO administration was eye irritation (30%). The totality of the ADR was classified as non-serious, and the 97.5% (n=80) was classified as mild and 2.5% as moderate (n=2). No cases under the severe category were identified. (4) Conclusion: No new risks were found in the population where this study was conducted.

scholarly journals Operation Save the World from Adverse Drug Reactions: findings from a drug safety surveillance programme in Nigeria

2019 ◽  
Vol 7 ◽  
pp. S46 ◽  
Author(s):  
Yohanna Kambai Avong ◽  
Bolajoko Jatau ◽  
Gbenga Ayodele Kayode ◽  
Blessing Ukpabi ◽  
Eunice Bosede Avong ◽  
...  
Keyword(s):  
Adverse Drug Reactions ◽  
Drug Safety ◽  
Drug Reactions ◽  
Surveillance Programme ◽  
Safety Surveillance ◽  
Drug Safety Surveillance ◽  
The World

scholarly journals Comparative study on drug safety surveillance between medical students of Malaysia and Nigeria

2015 ◽  
pp. 1015
Author(s):  
Mainul Haque ◽  
Abubakar Abdullahi Rabiu ◽  
Salwani Binti Ismail ◽  
Nor Iza A Rahman
Keyword(s):  
Medical Students ◽  
Comparative Study ◽  
Drug Safety ◽  
Safety Surveillance ◽  
Drug Safety Surveillance

scholarly journals The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study

2006 ◽  
Vol 15 (9) ◽  
pp. 675-682 ◽  
Author(s):  
Willemijn M. Meijer ◽  
Martina C. Cornel ◽  
Helen Dolk ◽  
Hermien E. K. de Walle ◽  
Nicola C. Armstrong ◽  
...  
Keyword(s):  
Congenital Anomaly ◽  
Drug Safety ◽  
Descriptive Study ◽  
European Network ◽  
Safety Surveillance ◽  
Drug Safety Surveillance
Sign in / Sign up

Export Citation Format

Share Document